Screening for ovarian cancer does not improve clinical outcomes in asymptomatic women without a family history of the disease. Screening did not decrease all-cause mortality, ovarian cancer mortality or the risk of diagnoses of advanced stage ovarian cancer. There is no demonstrable benefit on mortality following transvaginal ultrasonography or routine pelvic screening examinations and the use of CA125 or other biomarkers for ovarian cancer but such screening resulted in false-positive tests, overdiagnosis, and overtreatment with inevitable complications.
Conditions: Ovarian cancer
Diagnostic Tests: Transvaginal ultrasonography , routine pelvic screening examinations, CA125 biomarkers
View PDF
Sources
- Buhling KJ, et al. The role of transvaginal ultrasonography for detecting ovarian cancer in an asymptomatic screening population: a systematic review. Arch Gynecol Obstet. 2017 May;295(5):1259-1268. (PubMed)
- Guirguis-Blake JM, et al. Periodic Screening Pelvic Examination: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017 Mar 7;317(9):954-966. (PubMed)
- Luzak A, et al. Clinical effectiveness of cancer screening biomarker tests offered as self-pay health service: a systematic review. Eur J Public Health. 2016 Jun;26(3):498-505. (PubMed)
- Pinsky PF, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. Gynecol Oncol. 2016 Nov;143(2):270-275. (PubMed)
- Reade CJ, et al. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2013 Sep;130(3):674-81. (PubMed)
- US Preventive Services Task Force, et al. Screening for Gynecologic Conditions With Pelvic Examination: US Preventive Services Task Force Recommendation Statement. JAMA. 2017 Mar 7;317(9):947-953. (PubMed)